Sodium-Glucose Cotransporter 2 Inhibitors and Mycotic Genital or Urinary Tract Infections in Heart Failure
Authors:
- 25 April 2024
- journal article
- review article
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 30 (8) , 1031-1040
Abstract
No abstract availableKeywords
Funding Information
- UT Southwestern Medical Center
This publication has 50 references indexed in Scilit:
- SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefitsDiabetologia, 2022
- Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: An Updated Meta-AnalysisESC Heart Failure, 2022
- Outcome trial data on sodium glucose cotransporter-2 inhibitors: Putting clinical benefits and risks in perspectiveInternational Journal of Cardiology, 2022
- Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing SurveillanceAdvances in Therapy, 2021
- Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection FractionCurrent Heart Failure Reports, 2021
- Sodium–glucose cotransporter 2 inhibitors and risk of nephrolithiasisDiabetologia, 2021
- Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes MellitusAdvances in Therapy, 2020
- Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trialsDiabetes Research and Clinical Practice, 2019
- SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trialsActa Diabetologica, 2018
- Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical TrialsAdvances in Therapy, 2017